ArticleJournal of advanced research2026
Multi-omics elucidation of recombinant collagen-mediated modulation of mesenchymal stem cell functions.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRegenerative medicine leverages the potential of mesenchymal stem cells (MSCs) and biomaterials to overcome the limitations of traditional organ transplantation. Collagen, a key extracellular matrix component, is widely used, yet its molecular interactions with MSCs remain insufficiently understood.
objectivesThis study investigates how recombinant collagens modulate MSC behavior and paracrine functions to inform the development of bioactive scaffolds for tissue regeneration.
methodsRecombinant type I and III collagens were biosynthesized using Pichia pastoris. Multi-omics analyses, including transcriptomics and proteomics, were conducted to evaluate the effects of these collagens on MSC gene expression, secretory profiles, and functional impacts on fibroblasts, endothelial cells, and macrophages.
resultsRecombinant collagens regulated key MSC pathways related to angiogenesis, wound healing, adhesion, cytoskeletal organization, and osteogenesis. Proteomic data further revealed enhanced secretion of cytokines and growth factors that influenced the behavior of surrounding stromal and immune cells.
conclusionRecombinant collagen, as a bioactive material, can remodel the functions of mesenchymal stem cells. Specifically, recombinant type I collagen primarily activates the FAK/RHOA/ROCK signaling pathway, while recombinant type III collagen activates the PI3K/Akt signaling pathway; in contrast, bovine-derived type I collagen mainly regulates glycolysis. These findings further support the potential of recombinant collagen in constructing regenerative medicine scaffolds with intelligent regulatory functions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.